|
FAF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.57061039121709E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.05939709729819E-11 |
| Normal-vs-Stage2 |
5.828900E-04 |
| Normal-vs-Stage3 |
1.18319798403377E-11 |
| Normal-vs-Stage4 |
1.83364434747091E-12 |
| Stage1-vs-Stage2 |
8.504500E-02 |
| Stage1-vs-Stage3 |
9.560000E-02 |
| Stage1-vs-Stage4 |
4.877400E-03 |
| Stage2-vs-Stage3 |
1.261710E-02 |
| Stage2-vs-Stage4 |
9.239200E-04 |
| Stage3-vs-Stage4 |
1.752210E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.24278406746726E-13 |
| Normal-vs-AfricanAmerican |
6.363600E-04 |
| Normal-vs-Asian |
4.1549999996171E-08 |
| Caucasian-vs-AfricanAmerican |
2.820200E-01 |
| Caucasian-vs-Asian |
9.774800E-01 |
| AfricanAmerican-vs-Asian |
3.773000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.86789522422282E-11 |
| Normal-vs-Female |
7.38953342960258E-12 |
| Male-vs-Female |
6.658000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.49430525917683E-11 |
| Normal-vs-Age(41-60Yrs) |
1.6721002360498E-10 |
| Normal-vs-Age(61-80Yrs) |
5.7027049749081E-11 |
| Normal-vs-Age(81-100Yrs) |
9.236800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.200200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.370600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.584800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.267000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.947400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.058600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.315700E-03 |
| Classical-VS-Follicular |
4.968000E-01 |
| Classical-VS-Other |
2.076000E-01 |
| Classical-VS-Normal |
4.705602574262E-11 |
| Tall-VS-Follicular |
6.406400E-04 |
| Tall-VS-Other |
7.375400E-01 |
| Tall-VS-Normal |
1.46399559142196E-11 |
| Follicular-VS-Other |
2.010400E-01 |
| Follicular-VS-Normal |
1.79349999995804E-06 |
| Other-VS-Normal |
2.437000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.8461999706787E-09 |
| Normal-vs-N1 |
4.51794157640961E-12 |
| N0-vs-N1 |
2.130100E-02 |
|
|
